Novo Nordisk Launches Rebinyn in the US for People with Hemophilia B

On February 8, 2018, Novo Nordisk officially launched REBINYN, a GlycoPEGylated, Recombinant Coagulation Factor IX, for the treatment of Hemophila B. The BLA for Rebinyn was initially approved on May 31, 2017, and is indicated for on-demand treatment and control of sporadic bleeding episodes and during surgery in adults and children with hemophilia B.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.